TABLE 5.

MVEV-specific antibody responses^a

Mouse strain	Virus	Dose (PFU)	Route	No. of animals/group	Mean log10 antibody titer (SD)b		Mean PRNT50 titer (range)c
					First bleed	Second bleed	First bleed	Second bleed
C57BL/6	MVEV.wtd	103	i.m.	2	4.2 (0.4)	4.1 (0.6)	320 (pool)	60 (40–80)
	MVEV.C-IRES	105		10	4.0 (0.3)	4.7 (0.3)	40 (pool)	192 (80–320)
	MVEV.IFN-β	105		10	2.5 (0.5)	3.7 (0.4)	10 (pool)	50 (<10–80)
	MVEV.wte	103	i.v.	4	4.0 (0.2)	4.3 (0.2)	160 (pool)	120 (80–160)
	MVEV.IFN-β	103		5	<2.0	2.6 (0.6)	<10 (pool)	<10 (pool)
	MVEV.IFN-β	105		5	4.0 (0.1)	5.3 (0)	10 (pool)	180 (80–320)
BALB/c	MVEV.wtf	105	i.m.	6	3.6 (0.3)	4.2 (0.1)	20 (pool)	113 (40–160)
	MVEV.C-IRES	105		10	2.8 (0.4)	4.3 (0.4)	10 (pool)	82 (20–160)
	MVEV.IFN-β	105		10	2.5 (0.3)	4.2 (0.3)	<10 (pool)	15 (<10–40)
	MVEV.wt	105	s.c.	10	NTg	3.3 (0.3)	NT	20 (pool)
	MVEV.C-IRES	105		10	NT	3.7 (0.3)	NT	20 (pool)
	MVEV.IFN-β	105		10	NT	3.1 (0.1)	NT	<10 (pool)

^aGroups of 7- to 8-week-old C57B6 or BALB/c mice were immunized with wild-type or recombinant MVEV using the dose and route indicated and were boosted with the same dose and by the same route 3 to 4 weeks later. Sera were collected prior to delivery of the booster dose and at 3 to 4 weeks after the second immunization.

^bELISA endpoint titers of individual test sera were determined as described in Materials and Methods section.

^cPlaque reduction neutralization by individual or pooled test sera against MVEV were determined as described in Materials and Methods.

^dThree mice succumbed to MVEV.wt infection; the indicated group size represents surviving mice.

^eOne mouse succumbed to MVEV.wt infection; the indicated group size represents surviving mice.

^fFour mice succumbed to MVEV.wt infection; the indicated group size represents surviving mice.

^gNT, not tested.